This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.90% per year. These returns cover a period from January 1, 1988 through December 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical: Archive
KRYS Reports Preliminary Results for 2025, Outlines 2026 Objectives
by Zacks Equity Research
On a preliminary unaudited basis, Krystal Biotech expects revenues of $388-$389M in 2025. The company ended the year with $955M cash, and outlined 2026 plans as its pipeline advances.
FOLDNo Net Change CRMDNegative Net Change KRYSPositive Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
Implied Volatility Surging for Ardent Health Stock Options
by Zacks Equity Research
Investors need to pay close attention to ARDT stock based on the movements in the options market lately.
ARDTNegative Net Change
medical
PCRX Stock Down 10% as Preliminary Q4 Revenues Miss Estimates
by Zacks Equity Research
Pacira BioSciences stock slides nearly 10% after preliminary Q4 revenues of $196.9 million miss estimates, despite Exparel sales topping forecasts.
FOLDNo Net Change PCRXNegative Net Change CRMDNegative Net Change INDVNegative Net Change
biotechnology biotechs medical pharmaceuticals
TEVA Signs Deal With RPRX to Accelerate Development of Vitiligo Drug
by Zacks Equity Research
Teva strikes a $500M funding deal with Royalty Pharma for the speedy development of its vitiligo candidate, TEV-'408, while keeping global commercial control.
TEVAPositive Net Change RPRXPositive Net Change CRMDNegative Net Change INDVNegative Net Change
biotechnology biotechs medical pharmaceuticals
Hims & Hers Expands Platform-Led Access to Provider-Directed Care
by Debanjana Dey
HIMS broadens access to provider-led care with new offerings in diagnostics, hormonal health and at-home testing.
MEDPositive Net Change GDRXPositive Net Change HIMSPositive Net Change
medical medical-devices
GeneDx Partners With Komodo Health to Advance Rare Disease Research
by Zacks Equity Research
WGS collaborates with Komodo Health to link genomic data with real-world insights, expanding data monetization and strengthening its role in rare disease research.
BSXNegative Net Change ISRGNegative Net Change MEDPPositive Net Change WGSNegative Net Change
medical medical-devices
Exelixis Posts Preliminary '25 Results, Issues '26 Outlook
by Zacks Equity Research
EXEL posts approximately $2.32B in 2025 revenues and guides $2.525 -$2.625B for 2026 as Cabometyx grows and a zanzalintinib NDA advances.
RHHBYNegative Net Change EXELPositive Net Change FOLDNo Net Change CRMDNegative Net Change
biotechnology biotechs medical pharmaceuticals
INSM Stock Jumps on 2025 Preliminary Sales, 2026 Goals Announced
by Zacks Equity Research
Shares of Insmed rise after it tops FY25 sales forecasts, led by strong Brinsupri uptake, and outlines 2026 guidance and pipeline milestones.
INSMNegative Net Change CRMDNegative Net Change KROSNegative Net Change
biotechs medical
RVTY & Eli Lilly Partner to Expand Access to AI Drug Discovery Models
by Zacks Equity Research
Revvity teams up with Eli Lilly to bring TuneLab AI models to Signals Xynthetica, aiming to unlock secure, federated drug discovery at scale.
CRLNegative Net Change VCYTPositive Net Change CDNAPositive Net Change RVTYNegative Net Change
medical medical-devices
Take the Zacks Approach to Beat the Markets: Indivior, FIGS & Ulta Beauty in Focus
by Santanu Roy
Zacks highlights how Indivior, FIGS and Ulta Beauty delivered outsized gains as its ranks, recommendations and focus lists beat a volatile market.
ACNPositive Net Change MMMPositive Net Change SBUXPositive Net Change FORMPositive Net Change ULTANegative Net Change HIIPositive Net Change AMKRNegative Net Change MTDPositive Net Change FIVEPositive Net Change NOBLPositive Net Change FIGSPositive Net Change INDVNegative Net Change
aerospace computers medical medical-devices multi-sector-conglomerates restaurants retail semiconductor
Buy These 5 Dividend Growth Stocks Amid Conflicting Labor Market Data
by Aparajita Dutta
Dividend-growth stocks like CAH stand out as labor data sends mixed signals, offering income stability and growth amid economic uncertainty.
CAHPositive Net Change KGCPositive Net Change DCIPositive Net Change WWDPositive Net Change FOXPositive Net Change
aerospace basic-materials consumer-discretionary industrial-products medical
Illumina's New Connected Multiomics Platform Set to Boost Its Stock
by Zacks Equity Research
ILMN's Connected Multiomics, launched after early user input, advances precision health research and may boost the stock.
BSXNegative Net Change ILMNPositive Net Change IDXXPositive Net Change STEPositive Net Change
medical medical-devices
3 Medical Supplies Stocks That Beat the Market Despite Macro Headwinds
by Indrajit Bandyopadhyay
Cardinal Health, McKesson, and Cencora are showing how scale, specialty focus, and execution can drive market-beating returns despite macro pressure.
CAHPositive Net Change MCKPositive Net Change CORPositive Net Change
medical medical-devices
Tempus AI Stock Rallies 105% in a Year: Should Investors Still Hold?
by Sridatri Sarkar
TEM has surged 105% in a year on AI-driven growth, FDA clearances and improving margins, but GAAP losses still cloud the outlook.
EXASPositive Net Change GEHCNegative Net Change TEMPositive Net Change
medical
Neogen's Q2 Earnings and Revenues Beat Estimates, Stock Climbs
by Zacks Equity Research
NEOG's Q2 EPS and revenues top estimates, sending shares up 31.6% as the company raises its fiscal 2026 revenue and EBITDA outlook.
MDTNegative Net Change FMSPositive Net Change PBHPositive Net Change NEOGNegative Net Change
earnings medical medical-devices
New Strong Buy Stocks for January 12th
by Zacks Equity Research
ERO, NU, KSS, FLGT and BODI have been added to the Zacks Rank #1 (Strong Buy) List on Jan.12, 2026.
KSSNegative Net Change NUNegative Net Change EROPositive Net Change FLGTPositive Net Change BODIPositive Net Change
consumer-discretionary finance medical
Betting on a Boom: 3 Healthcare ETFs for 2026 and Beyond
by Aparajita Dutta
After a late-2025 rebound eased policy fears, healthcare ETFs like IXJ are gaining attention as investors position for a sector comeback in 2026.
AZNNegative Net Change LLYPositive Net Change XLVNegative Net Change VHTNegative Net Change IXJNegative Net Change
etfs medical
PacBio Stock Dips Post Latest Launch to Expand Multiomics Capabilities
by Zacks Equity Research
PACB introduces CiFi, a new sequencing method designed to expand multiomics capabilities without added hardware.
BSXNegative Net Change CAHPositive Net Change IDXXPositive Net Change PACBPositive Net Change
medical medical-devices
SENS Stock Up as Eversense 365 Enters AID Market With twiist System
by Zacks Equity Research
Senseonics shares gain after Eversense 365 became the first one-year implantable CGM integrated with an automated insulin delivery system.
BSXNegative Net Change ISRGNegative Net Change SENSNegative Net Change MEDPPositive Net Change
medical medical-devices
J&J Strikes Drug Pricing Deal With Trump, Gets Tariff Reprieve
by Zacks Equity Research
JNJ cuts U.S. drug prices under a Trump deal, gains a tariff reprieve, and accelerates a $55 billion push to expand domestic manufacturing.
AZNNegative Net Change JNJPositive Net Change LLYPositive Net Change ABBVNegative Net Change
biotechnology biotechs medical pharmaceuticals
Here's Why Biotech ETFs Are Rallying Hard
by Sanghamitra Saha
Biotech rally gains steam on valuations, rate cuts, FDA wins & M&A. IBB, XBI, CANC and IDNA are ETFs near one-year highs.
IBBNegative Net Change SPYPositive Net Change XBINegative Net Change IDNANegative Net Change CANCNegative Net Change
etfs medical
VKTX Completes Enrollment in Phase I Maintenance Study of Obesity Drug
by Zacks Equity Research
Viking Therapeutics completes enrollment in a phase I maintenance study of VK2735, testing flexible oral and injectable dosing after initial weight loss in obese adults.
NVOPositive Net Change LLYPositive Net Change VKTXNegative Net Change GPCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
3 MedTech Stocks That Crushed the S&P 500 Over the Past Year
by Indrajit Bandyopadhyay
TransMedics, KORU Medical Systems and Cardinal Health beat the S&P 500 as execution, earnings visibility and company-specific catalysts drove gains.
CAHPositive Net Change TMDXNegative Net Change KRMDPositive Net Change
medical medical-devices
Bayer Accelerates Growth With siRNA, AI Deals and Pipeline Progress
by Zacks Equity Research
Bayer AG enters into collaborations to develop a heart-targeted siRNA therapy and AI technology, expanding its push into next-gen genetic medicines.
JNJPositive Net Change BAYRYPositive Net Change FOLDNo Net Change CRMDNegative Net Change
biotechnology biotechs medical pharmaceuticals
BMY Rallies 17.3% in Six Months: Buy, Sell or Hold the Stock?
by Ekta Bagri
BMY shares have surged in the past six months, driven by Opdivo, Reblozyl and a guidance raise, as growth drugs offset mounting generic pressure
BMYNegative Net Change PFENegative Net Change MRKNegative Net Change BNTXPositive Net Change
biotechnology biotechs medical pharmaceuticals